Clear Cell Renal Cell Carcinoma Subtypes Identified with Genetic Test
the Cancer Therapy Advisor take:
According to a study published in the journal European Urology, researchers at the Singapore General Hospital and National Cancer Centre Singapore A*STAR Institute of Bioengineering and Nanotechnology have developed a genetic test that can identify subtypes of clear cell renal cell carcinoma (ccRCC).
Clear cell renal cell carcinoma is the most common type of kidney cancer, but the prognosis of those patients can be difficult to predict as there are different subtypes of the disease.
In order to identify genes that could be used as genetic markers for the test, researchers analyzed the genetic material from 279 patients who had ccRCC in the last 15 years.
The team was able to identify eight genes that were expressed in differing levels between subtypes of ccRCC. Then, they developed an assay based on these eight genes to test patients with ccRCC. When they tested it on patients with ccRCC, they found that it was a reliable predictor of a good or poor prognosis.
Furthermore, the test could also reliably predict whether patients will benefit from tyrosine kinase inhibitor (TKI) therapy. The findings suggest that this genetic test could be used for both prognosis and prediction for patients with ccRCC, but further clinical studies are warranted in order to determine its value.
A genetic test can identify subtypes of clear cell renal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia